RFA-NS-22-031: Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $275,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 21, 2022.
From the official notice on Grants.gov, last changed September 20, 2022. Checked November 7, 2026.
- Award ceiling$275,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU24
- Clinical trialsNot allowed
- Funded byNINDS
- Median yearly award$431,540
- Typical project length10 years
- U24, Resource-Related Research Project Cooperative Agreement. Shared research resources such as data centers or coordinating centers, with substantial NIH involvement. Other open U24 notices.
Projects funded under RFA-NS-22-031 were run by National Institute of Neurological Disorders and Stroke (NINDS, 13 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-NS-22-031 in the NIH Guide.
Key dates
| Posted | September 20, 2022 |
|---|---|
| Deadline | November 21, 2022 |
| Archived by Grants.gov | December 27, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $431,540; it allows up to $275,000 per award.
- Most of the program's money (76% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network provides a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network is not specific to one disease, it has the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for Clinical Sites. Separate FOAs solicit applications for the Clinical Coordinating Center and the Data Coordinating Center.
Funded under RFA-NS-22-031 so far
NIH funded 13 projects under RFA-NS-22-031 in fiscal 2023 to 2026, at 13 institutions. The median yearly award was $431,540.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-NS-22-031 still open?
No. It closed on November 21, 2022.
Who can apply for Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)?
Closed November 21, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $275,000 each.
Who has been funded under RFA-NS-22-031?
NIH RePORTER lists 13 projects funded under RFA-NS-22-031 in fiscal 2023 to 2026, at 13 institutions. The most were at Vanderbilt University Medical Center, Utah State Higher Education System--University of Utah, Hugo W. Moser Res Inst Kennedy Krieger.
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?
The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Microplastics Research and Resource Coordination Center (U24 - Clinical Trial Not Allowed)
- IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
- Network of the National Library of Medicine Training Center (U24 Clinical Trial Not Allowed)
- Network of the National Library of Medicine Coordinating Center (U24 Clinical Trial Optional)